4D Molecular Therapeutics, Inc. FDMT 深 沪
已收盘 10-09 16:00:00 美东时间
13.33
+0.630
+4.96%
华盛通- 最 高13.85
- 今 开12.70
- 成交量 86.81万股
- 最 低 12.55
- 昨 收 12.70
- 总市值 7.36亿
- 52周最高 16.93
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 6.96
- 委 比 26.00%
- 总股本 5524.42万
- 历史最高 55.11
- 量 比 0.74
- 振 幅 10.24%
- 历史最低 2.235
- 每 手 1
- 风险率 2.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
10-06 20:26
4DMT to Host Investor Day on October 21, 2026
4DMolecular Therapeutics will host an Investor Day on October 21, 2026, in New York City, featuring insights on 4D-150's clinical profile and commercial vision, as well as discussions with leading retinal experts. The event will include a Company presentation, expert panel sessions, and a Q&A. Registration is available online, and an archived webcast will be accessible for up to one year. 4D-150 is a sustained-release anti-VEGF therapy for retina...
10-05 12:00
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
4DMT Molecular enters phase 3 trial of 4D-150 for diabetic eye disease
4D Molecular Therapeutics (FDMT) announced on Monday that it has started enrolling patients in a Phase 3 trial of 4D-150 for diabetic macular edema (DME), adding a new clinical catalyst for investors....
09-28 22:25
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of Scholastic Corporation (NASDAQ:SCHL) fell sharply in pre-market trading after the company reported downbeat results for the first quarter. The company posted quarterly losses of $3.63 per...
09-25 20:03
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Compass Point analyst Ed Engel upgraded Coinbase Global Inc (NASDAQ:COIN) from Sell to Neutral an...
09-14 20:31
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
09-14 19:03
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 96,000 RSUs to seven new non-executive employees under its 2025 Employment Inducement Award Plan. The company is advancing innovative therapeutics, including 4D-150 for treating retinal vascular diseases and 4D-710 for cystic fibrosis. All product candidates remain in clinical or preclinical development and are not yet approved for marketing.
09-11 20:05
